Autolus Therapeutics plc Other Current Liabilities
Autolus Therapeutics plc (AUTL) had Other Current Liabilities of $2.46 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Other Liabilities, Current $2.46M.
- 2026-03-31: Other Liabilities, Current $2.61M.
- 2025-12-31: Other Liabilities, Current $2.03M.
- 2025-09-30: Other Liabilities, Current $2.36M.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $2.46M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $2.61M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $2.03M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $2.36M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $2.15M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $2.38M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $479.00K 10-K · filed 2026-03-27 | |
| 2024-09-30 | $403.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $382.00K 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $570.00K 10-Q · filed 2024-05-17 | |
| 2023-12-31 | $533.00K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $483.00K 10-Q · filed 2023-11-09 | |
| 2022-12-31 | $393.00K 10-K · filed 2024-03-21 | |
| 2021-12-31 | $160.00K 20-F · filed 2023-03-07 | $150.00K 20-F · filed 2022-03-10 |
| 2021-03-31 | $574.00K 6-K · filed 2021-05-06 | |
| 2020-12-31 | $496.00K 20-F · filed 2022-03-10 | |
| 2020-09-30 | $402.00K 6-K · filed 2020-11-05 | |
| 2020-06-30 | $247.00K 6-K · filed 2020-08-06 | |
| 2020-03-31 | $955.00K 6-K · filed 2020-05-07 | |
| 2019-12-31 | $716.00K 20-F · filed 2021-03-04 | |
| 2019-09-30 | $493.00K 6-K · filed 2019-11-07 | |
| 2019-06-30 | $1.34M 6-K · filed 2019-08-08 | |
| 2018-12-31 | $447.00K 20-F · filed 2020-03-03 | $1.07M 20-F · filed 2019-02-25 |
| 2018-09-30 | $623.00K 20-F · filed 2019-02-25 | |
| 2017-09-30 | $589.00K 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |